Bellevue

An investment of 10,000 CHF in Bellevue three years ago would be worth only 3,536.59 CHF at the current closing price of 6.96 CHF, representing a loss of 64.63%. The closing price at the time of purchase was 19.68 CHF, which would have resulted in 508.13 Bellevue shares. The most recent market capitalization is 92.91 million CHF; stock splits and dividends were not taken into account in the calculation. » Więcej na finanzen.net

Bellevue Group reports a group profit of CHF 1.8 million for H1 2026, operating income of CHF 26.2 million (+4.4%) and reduced operating expenses to CHF 23.8 million (-3.2%) thanks to initiated cost-cutting measures; expenses include one-off write-downs of CHF 0.6 million. Assets under management fell to CHF 4.8 billion (-8.7%), driven by negative performance in medtech/healthcare and net outflows of around CHF 490 million. Positive factors included the strong performance of BB Biotech (+14.1% share-price increase) and inflows of CHF 37 million into several strategies; Bellevue is positioning itself for an expected recovery in the healthcare sector and is focusing on distribution, technology and efficiency gains. » Więcej na de.investing.com

Asset manager Bellevue reports a sharp drop in profits for 2025. The cause was weakness in the healthcare sector and the depreciation of the US dollar, which weighed on results. » Więcej na finanzen.net